Aptus Capital Advisors LLC Buys 2,358 Shares of AbbVie Inc. $ABBV

Aptus Capital Advisors LLC lifted its stake in shares of AbbVie Inc. (NYSE:ABBV) by 1.7% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 137,505 shares of the company’s stock after acquiring an additional 2,358 shares during the period. Aptus Capital Advisors LLC’s holdings in AbbVie were worth $31,419,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the stock. Bank of Jackson Hole Trust lifted its holdings in shares of AbbVie by 0.6% in the 4th quarter. Bank of Jackson Hole Trust now owns 7,213 shares of the company’s stock worth $1,648,000 after acquiring an additional 44 shares during the last quarter. Eclectic Associates Inc. ADV lifted its holdings in shares of AbbVie by 0.8% in the 4th quarter. Eclectic Associates Inc. ADV now owns 5,852 shares of the company’s stock worth $1,337,000 after acquiring an additional 45 shares during the last quarter. Weil Company Inc. lifted its holdings in shares of AbbVie by 2.3% in the 3rd quarter. Weil Company Inc. now owns 2,026 shares of the company’s stock worth $469,000 after acquiring an additional 46 shares during the last quarter. Hardin Capital Partners LLC lifted its holdings in shares of AbbVie by 1.4% in the 4th quarter. Hardin Capital Partners LLC now owns 3,321 shares of the company’s stock worth $759,000 after acquiring an additional 46 shares during the last quarter. Finally, Dogwood Wealth Management LLC lifted its holdings in shares of AbbVie by 10.8% in the 4th quarter. Dogwood Wealth Management LLC now owns 473 shares of the company’s stock worth $108,000 after acquiring an additional 46 shares during the last quarter. 70.23% of the stock is owned by institutional investors.

AbbVie Price Performance

NYSE:ABBV opened at $227.54 on Friday. The firm’s 50-day moving average price is $211.05 and its 200-day moving average price is $219.07. The company has a market capitalization of $402.02 billion, a PE ratio of 112.09, a P/E/G ratio of 0.70 and a beta of 0.32. AbbVie Inc. has a 1-year low of $181.73 and a 1-year high of $244.81.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.59 by $0.06. The company had revenue of $15 billion for the quarter, compared to analysts’ expectations of $14.72 billion. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. AbbVie’s revenue was up 12.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.46 EPS. Equities analysts anticipate that AbbVie Inc. will post 14.3 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on ABBV shares. Cantor Fitzgerald restated an “overweight” rating and issued a $240.00 price objective on shares of AbbVie in a report on Thursday, April 30th. Evercore set a $235.00 target price on shares of AbbVie in a research note on Friday, May 15th. Barclays started coverage on shares of AbbVie in a research note on Thursday, February 19th. They issued an “overweight” rating and a $275.00 target price on the stock. William Blair reaffirmed an “outperform” rating on shares of AbbVie in a research note on Monday, March 9th. Finally, Piper Sandler lifted their target price on shares of AbbVie from $294.00 to $298.00 and gave the stock an “overweight” rating in a research note on Thursday, May 14th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $253.43.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie said nine-year CLL14 data showed venetoclax plus obinutuzumab delivered durable progression-free survival in previously untreated chronic lymphocytic leukemia, strengthening the case for the drug’s long-term commercial value. AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results
• Positive Sentiment: Investors are also focused on AbbVie’s broader pipeline and franchise strength, with commentary pointing to Skyrizi and Rinvoq continuing to drive revenue growth, which supports the company’s outlook beyond legacy Humira. Will Skyrizi & Rinvoq Continue to Drive AbbVie’s Topline Through 2026?
• Neutral Sentiment: Several market commentaries described AbbVie as a defensive, high-quality compounder, but noted the shares may not be cheap at current levels, which suggests valuation may temper upside even with strong fundamentals. AbbVie: A Defensive Compounder Worth Holding, But Not A Bargain Buy
• Negative Sentiment: One article highlighted regulatory risk around AbbVie’s fast-acting neurotoxin TrenibotE after an FDA complete response letter, which could delay a potential growth driver if development setbacks persist. FDA Issues Complete Response Letter for AbbVie’s Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.